<div id="readability-page-1"><h3>Claim 50% Off TipRanks Premium</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential</li></ul>Lexeo Therapeutics, Inc. ( (LXEO) ) has shared an update. On January 27, 2026, Lexeo Therapeutics, Inc. announced that its Board of Directors appointed its current Chief Technical Officer, Jose Manuel Otero, Ph.D., as Chief Operating Officer, effective January 2, 2026, with an updated annual base salary of $510,000 and confirmation that there are no related-party arrangements or conflicts of interest associated with his promotion. The company also reported a leadership transition in its medical organization, with the Board appointing Narinder P. Bhalla, M.D., as Chief Medical Officer effective January 20, 2026, succeeding Eric Adler, M.D., who will become President and Chief Executive Officer of Myoventive, Inc., while stepping down as a Lexeo executive officer as of January 27, 2026 but continuing to serve the company as a senior clinical and scientific advisor, signaling continuity in scientific leadership amid broader expansion in the cardiac precision medicines space. The most recent analyst rating on (LXEO) stock is a Hold with a $7.50 price target. To see the full list of analyst forecasts on Lexeo Therapeutics, Inc. stock, see the LXEO Stock Forecast page. Spark’s Take on LXEO Stock According to Spark, TipRanks’ AI Analyst, LXEO is a Neutral. Overall score reflects high financial risk from zero revenue, widening losses, and substantial ongoing cash burn, reinforced by a weak technical setup. Offsetting factors include a relatively low-leverage balance sheet, supportive financing, and encouraging interim clinical trial data. To see Spark’s full report on LXEO stock, click here. More about Lexeo Therapeutics, Inc. Lexeo Therapeutics, Inc. is a biotechnology company focused on developing precision cardiac medicines, including through collaborations and venture-backed initiatives such as Myoventive, Inc., a cardiac precision medicines company it co-founded in June 2025 with Perceptive Xontogeny Venture Funds and venBio Partners. Average Trading Volume: 1,400,862 Technical Sentiment Signal: Hold Current Market Cap: $548.1M For an in-depth examination of LXEO stock, go to TipRanks’ Overview page.</div>

SBIO

LXEO

Lexeo Therapeutics, Inc. announced key executive leadership changes, appointing Jose Manuel Otero, Ph.D., as Chief Operating Officer effective January 2, 2026, with an annual salary of $510,000. Narinder P. Bhalla, M.D., will become Chief Medical Officer on January 20, 2026, succeeding Eric Adler, M.D., who will step down but remain as a senior advisor. The company focuses on precision cardiac medicines and currently has a Hold rating with a $7.50 price target for its stock (LXEO).

Lexeo Therapeutics Announces Key Executive Leadership Changes